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Summary
-catenin plays an important role in development and homeostasis. Deregulated -catenin is involved in oncogenesis. In
this study, we found that -catenin can physically complex with NF-B, resulting in a reduction of NF-B DNA binding,
transactivation activity, and target gene expression. Repressed NF-B activity is found in human colon cancer cells in
which -catenin is activated. Importantly, activated -catenin was found to inhibit the expression of NF-B target genes,
including Fas and TRAF1. Furthermore, a strong inverse correlation was identified between the expression levels of
-catenin and Fas in colon and breast tumor tissues, suggesting that -catenin regulates NF-B and its targets in vivo.
Thus, -catenin may play an important role in oncogenesis through the crossregulation of NF-B.
Introduction fraction of other types of cancers (Kinzler and Vogelstein, 1996).
Mutations in the -catenin (CTNNB1) gene sequences encoding
the crucial GSK-3 phosphorylation sites in -catenin’s N-ter--catenin plays two important roles in cells, as a protein associ-
ated with E-cadherin in cell-cell adhesion (Ben-Ze’ev and Gei- minal domain have been found in about 10% colorectal cancer,
as well as many other different cancer types (Polakis, 2000).ger, 1998), and as a transcriptional activator in Wnt signaling
(Willert and Nusse, 1998). Wnt signaling via -catenin plays a The fact that APC mutations and oncogenic-catenin mutations
are mutually exclusive in colon cancer suggests that the majorcentral role in development and homeostasis (Polakis, 2000). A
critical control of this pathway is the level of cytosolic -catenin, critical consequence of these mutations is the elevation of
-catenin levels in the cytoplasm and nucleus. Deregulation ofwhich determines the activation of Wnt responsive genes. With-
out stimulation, -catenin is degraded by the ubiquitin proteo- -catenin leads to constitutive formation of the -catenin/TCF
complex and altered expression of TCF target genes. Wnt/TCFsome pathway, which depends upon -catenin phosphorylation
(Orford et al., 1997). The phosphorylation of -catenin occurs in target genes in cancer cells, which likely cooperate in effecting
neoplastic transformation, include c-Myc (He et al., 1998), cyclina multiprotein complex composed of tumor suppressor protein
adenomatous polyposis coli (APC), Axin, and glycogen synthase D1 (Tetsu and McCormick, 1999), and MMP-7 (matrix metallo-
proteinase 7/matrilysin) (Crawford et al., 1999).kinase-3 (GSK-3). In this complex, GSK-3 phosphorylates the
N-terminal region of -catenin, marking -catenin for ubiquitina- The transcriptional factor NF-B is another important signal
transduction pathway that participates in the induction of a widetion-dependent proteolysis (Kikuchi, 1999). Wnt signaling inhib-
its -catenin phosphorylation, thus inducing the accumulation variety of cellular genes involved in immunity, inflammation, and
regulation of apoptosis (Bours et al., 2000; Ghosh et al., 1998;of cytosolic -catenin, which then associates with the TCF/
LEF family of transcription factors to activate Wnt/-catenin- Gilmore et al., 1996; Wang et al., 1999). The active complex of
NF-B is composed of two subunits, p65 and p50. Binding sitesresponsive genes (Behrens et al., 1998). Thus, -catenin phos-
phorylation controls -catenin protein level and Wnt signaling. for NF-B are present in the promoter region of many genes,
such as those encoding cell adhesion molecules, cytokines,Defects in Wnt signaling play a major role in human cancers
(Korinek et al., 1997; Morin et al., 1997). Inactive mutations and growth factors. NF-B exists in the cytosol of resting cells
bound to inhibitory IB- proteins (Baeuerle and Baltimore,of the APC tumor suppressor gene, which is the predominant
mechanism leading to -catenin deregulation, have been re- 1988). Stimulation with specific inducers, such as TNF or LPS,
activates the IB kinase (IKK) complex that phosphorylatesported in approximately 70%–80% of colorectal cancers and a
S I G N I F I C A N C E
-catenin is known to play two important functions—as an E-cadherin-associated protein in cell-cell adhesion, and as a transcriptional
activator, through its interaction with TCF in Wnt signaling. In this study, we identified a novel role of -catenin, as an inhibitor of
NF-B. -catenin exerts this function through physical interaction, which is independent of TCF-mediated transcription. Importantly,
-catenin can repress expression of NF-B target gene Fas. As deregulated -catenin and downregulation of Fas play a critical role
in tumor progression, the function identified in this study reveals a new direction for understanding the oncogenic roles of -catenin.
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IB-, triggering its degradation by the proteosome and al., 2000). These observations indicate that -catenin can inhibit
NF-B transcriptional activity.allowing free NF-B to translocate to the nucleus and activate
To determine whether the suppression of NF-B transactiva-gene expression (Gumbiner, 1995). High levels of NF-B activity,
tion is due to an effect on NF-B DNA binding, we performedwhich are associated with increased resistance to apoptosis
an electrophoretic mobility shift assay (EMSA). We noticed thatinduced by TNF and a variety of anticancer reagents, have been
both the basal level (Figure 1C, lanes 1 and 8) and the TNF-shown in diverse solid tumor-derived cell lines (Bours et al.,
induced level of DNA binding (Figure 1C, lanes 2–3 and 9–10)2000). However, NF-B plays a dual role in regulation of apopto-
were significantly reduced in the 293--catenin A cells as com-sis (Bours et al., 2000). NF-B has been also shown to be
pared to the parental cells. Quantification of the bands showsessential for Fas expression, to be a proapoptotic molecule
about 3- to 5-fold suppression (data not shown). Similar effects(Chan et al., 1999; Zheng et al., 2001), and to be required for
were observed with another stable transfectant, 293--cateninp53-mediated apoptosis under some circumstances (Ryan et
B cells (data not shown). The inhibition of NF-B by -cateninal., 2000).
is specific, since the DNA binding of Oct-1, another transcriptionFas (CD95/APO-1) is a cell surface “death receptor” belong-
factor used as an internal control, was not inhibited (Figure 1C,ing to the tumor necrosis factor receptor (TNFR) family. Fas is
bottom). Thus, -catenin has an inhibitory effect on NF-B DNAconstitutively expressed in normal colon epithelial cells which
binding activity.are sensitive to Fas-mediated apoptosis. Fas is downregulated
NF-B is known to inhibit TNF-induced apoptosis. To deter-in the majority of colon carcinomas, representing a mechanism
mine the effect of -catenin on this function of NF-B, wefor cancer cells to escape lymphocyte-mediated immune sur-
examined its effect in Saos-2 cells, which are sensitive to TNF-
veillance (O’Connell et al., 2000). NF-B RelA (p65) has been
induced apoptosis (Ryan et al., 2000). We transfected Saos-2
shown to be essential for induction of Fas expression, although cells with -catenin and/or -catenin plus p65, and then exam-
strong induction of Fas expression requires combination of mul- ined the survival cells after TNF treatment. We found that
tiple cytokines or mitogens (Ouaaz et al., 1999). Thus, in re-
-catenin enhanced TNF-induced cell death (Figure 1D, lane 3
sponse to TNF--induced apoptosis, NF-B functions as an compared to lane 2). Furthermore, the p65-mediated repression
antiapoptotic molecule. However, NF-B is required for Fas of TNF-induced cell death (Figure 1D, lane 4 compared to lane
expression and therefore has a positive role in Fas induced 2) was derepressed by -catenin (Figure 1D, lane 5 compared
apoptosis. This represents a dual role of NF-B in regulation of to lane 4), and -catenin-mediated sensitivity to TNF was re-
normal tissue homeostasis. duced by p65 (Figure 1D, lane 5 compared to lane 3), suggesting
Recently, GSK-3 has been shown to be required for NF- that the -catenin-mediated effect is through the NF-B path-
B activation (Hoeflich et al., 2000). As -catenin is a major way. Thus, -catenin is able to exert an inhibitory effect on
substrate of GSK-3, it raises an interesting possibility that NF-B.
-catenin might serve as a mediator for the crossregulation -catenin is known to function as a cotranscription factor for
between these two pathways. In this study, we found that TCF4-directed transcription (Korinek et al., 1997). To determine
-catenin can physically interact with NF-B and inhibit its activ- whether TCF4 signaling is involved, we examined the effect of
ity. Additionally, suppressed NF-B activity and NF-B target a dominant negative mutant TCF4 (dnTCF4) (Morin et al., 1997)
on -catenin-mediated inhibition of NF-B. Using a cotransfec-gene expression can be found in cancer cells expressing high
tion assay, we found that although dnTCF4 abrogated -cat-levels of -catenin. Importantly, -catenin was found to inhibit
enin-mediated activation of TOP, a reporter known to be acti-Fas expression through repression of NF-B. Furthermore, there
vated by the -catenin/TCF4 pathway (Korinek et al., 1997)is a strong inverse correlation of -catenin and Fas expression
(Figure 1E, right panel), it did not affect either -catenin-medi-in human breast and colon tumor tissues. Thus, this study pro-
ated inhibition on NF-B-driven reporter (Figure 1E, left) or p65-vides a mechanistic linkage between two important pathways
stimulated NF-B reporter (data not shown). Similarily, dnTCF4critical for oncogenesis, and also provides a novel mechanism
was not able to block -catenin mediated-sensitivity in Saos-2for -catenin-mediated tumor progression.
cells (data not shown). This indicates that -catenin-mediated
inhibition of NF-B does not go through the -catenin/TCF4Results
signaling pathway.
IB- is a major regulator of NF-B. To determine whether
-catenin inhibits NF-B activity
IB- is involved in this regulation, we examined the effect ofTo investigate the potential effect of-catenin on NF-B activity,
-catenin on IB- regulation by immunoblot. We found that
we first examined the effects of -catenin on a NF-B-driven overexpression of -catenin did not effect IB- regulation,
luciferase reporter that can be activated by either p65 or TNF. since there was no difference in either the phosphorylation or
Cotransfection of human epithelial kidney (HEK) 293 cells with the degradation of IB- between the 293 cells and the 293-
a fixed dose of p65 and increasing doses of either wild-type -catenin cells following TNF treatment (Figure 1F). Therefore,
-catenin or active mutant -cateninS37A (Orford et al., 1997) the inhibition of NF-B activity by -catenin occurs in an IB--
results in a dose-dependent suppression of luciferase activity and TCF4-independent manner.
(Figure 1A), suggesting that -catenin inhibits p65 transcrip-
tional activity. -catenin also inhibited the basal level B-lucifer- -catenin complexes with NF-B
ase (in the absence of exogenous p65) to a lesser extent, proba- T examine the possibility that -catenin may inhibit NF-B
bly due to suppression of endogenous p65 activity (data not through physical interaction, we tested whether -catenin and
shown). Likewise, TNF-induced NF-B activity was also sup- NF-B can form a complex. By a coimmunoprecipitation (IP)
pressed in 293--catenin A cells (Figure 1B), 293 cells stably assay, we found that both p65 and p50 were able to form a
complex with -catenin, either endogenous -catenin in the 293transfected with -cateninS45Y (another active mutant) (Lin et
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Figure 1. -catenin inhibits NF-B transcriptional and DNA binding activities
A: 293 cells were transfected with B-luc (0.1 g), p65 (0.2 g), -catenin, or active mutant -cateninS37A (-catS37A) (0.6, 1.2, 1.8 g).
B: 293 and 293 -cateninS45Y stable transfectants (293--cat A) were transfected with B-luc (0.1 g), with or without treatment of TNF, and basal levels
were normalized to 100%. Insert shows -catenin level by immunoblot.
C: NF-B DNA binding activity was measured by EMSA. Antibodies against p65, p50, p300, and -catenin were used for supershifting the complex. Oct-1
DNA binding activity by EMSA used as an internal control.
D: Saos-2 cells were transfected with pcmv--gal (0.1 g), p65 (0.6 g), IB- (0.6 g), -catenin (0.6 g), or p65 plus -catenin (0.6 g and 1.2 g) and
then treated with TNF (10 ng/ml) for 24 hr. Percent cell death was calculated from number of viable cells as compared to untreated.
E: 293 cells were transfected with B-luc (0.1 g, left) or TOP (0.1 g, right), p65 (0.2 g), -catenin (0.6 g), and dnTCF4 (1.2 g). There was no effect by
-catenin or dnTCF4 on the mutant reporter FOP (data not shown).
F: IB- level by immunoblot with or without TNF (10 ng/ml) treatment. In all transfection experiments, the total amount of DNA was kept constant with
transfection of the empty vector.
vector cells, or stably expressed -catenin in the 293--catenin enin does not interact with p65 or p50 alone (Figure 2B). How-
ever, in presence of cell lysate, both in vitro-translated, exoge-A and B cells (Figure 2A). This interaction is independent of
IB-, as it occurred regardless of TNF treatment, which re- nous p65 and p50 were able to bind -catenin (Figures 2C–2D).
This interaction did not occur when the endogenous p65- orduced the binding of IB- to NF-B due to IB- degradation
(Baeuerle and Baltimore, 1988) (Figure 2A). Expression of p50-depleted cell lysate were used (Figures 2C–2D, insert), sug-
gesting that additional factors that associate with endogenous-catenin does not change the protein levels of p65, p50 (Figure
2A), or IB- (Figure 1F). The interaction was also observed in p65 or p50 are required for the exogenous p65 and p50 to
interact with -catenin. The in vitro-translated p65 and p50MCF-7 cells, a breast cancer cell line, suggesting the interaction
as a general phenomenon (data not shown). To determine are in natural form, as a p65 antibody can bring down both
exogenous p65 and p50 (Figure 2C). The GST--catenin is alsowhether -catenin and NF-B can directly form a complex, we
translated p65 and p50 in vitro, and mixed them with GST-- in natural form, since it can bring down TCF4 protein (Figure
2D). Thus, -catenin is indeed able to complex with p65 andcatenin protein. By pulling down the GST--catenin-interacting
proteins using glutathione-agarose, we found that GST--cat- p50, although additional cellular factors are required.
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Figure 2. -catenin physically interacts with NF-B (p65 and p50)
A: Immunoprecipitation (IP) was performed with antibodies against p65 or p50 (normal IgG as a negative control). The complexes were then subjected
to immunoblot as indicated.
B: In vitro translated p65 and p50 (35S-Met labeled) were mixed with GST--catenin or GST alone, pulled down by glutathione-agarose, and subjected to
SDS-PAGE.
C and D: in vitro translated p65 and p50 proteins were mixed with GST--catenin or GST in the presence of whole or p65- or p50-depleted (by repeated
IP) cell lysates (RKO), and analyzed as in (B); inserts show loaded protein.
Since -catenin physically associates with NF-B compo- colon cancer cell lines, three of which have a high level of
-catenin (HCT116, DLD-1, and SW480), and one of which hasnents, we also asked whether -catenin is directly involved in
the NF-B-DNA complex. However, a supershift assay by EMSA a low level of -catenin (RKO) (Figure 3A). We found that TNF-
induced NF-B DNA binding activity was dramatically lower indoes not support this notion, as the -catenin antibody does
not affect the migration of the NF-B-DNA complex (Figure 1C, cells expressing high levels of -catenin (Figure 3B, top, lanes
3–8) compared with that in cells expressing low levels oflanes 7 and 13). Another molecule, p300, known to form com-
plex with both NF-B (Gerritsen et al., 1997; Perkins et al., 1997) -catenin (Figure 3B, top, lanes 1–2). The suppression is spe-
cific, since there was no significant difference in the controland -catenin (Hecht et al., 2000; Miyagishi et al., 2000; Sun
et al., 2000), also does not seem to be involved, as there is no (Oct-1) DNA binding (Figure 3B, bottom). Similarly, NF-B tran-
scriptional activity in response to TNF, as measured by a NF-B-effect in the DNA binding with p300 antibody (Figure 1D, lanes
6 and 12). Thus, -catenin may interact with NF-B and disrupt driven luciferase assay, was also lower in colon cancer cells
expressing high levels of -catenin (Figure 3C). The reducedthe ability of NF-B to bind to the DNA.
NF-B activity appears to correlate well with the increased
-catenin expression, since the other NF-B family (p65, p50,NF-B is suppressed in colon cancer cells
-catenin is frequently activated in colon cancer cells (Korinek and IB-) protein levels are similar among these cells (Figure
3A). To determine whether the downstream targets of NF-Bet al., 1997; Morin et al., 1997). As -catenin inhibits NF-B,
we asked whether NF-B activity could also be reduced in colon were also affected, we also examined the expression of TRAF1,
a downstream target gene of NF-B (Wang et al., 1998), incancer cells in which -catenin is activated. We examined four
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Figure 3. Reduced NF-B activity in human colon cancer cells that express high level of -catenin
A: Protein levels of -catenin, p65, p50, and IB- in colon cancer cell lines by immunoblot.
B: Top, EMSA analysis of NF-B DNA binding activity. TNF treatment was at 10 ng/ml for 15 min. Bottom, EMSA of Oct-1 used as an internal control. Lanes
are the same as in NF-B gel shifting unless specified by antibody used as indicated.
C: Colon cancer cell lines were transfected with B-luc (1.0 g) and then treated with TNF (1 ng/ml, 9 hr).
D and E: Immunoblot analysis of NF-B target gene TRAF1 (TNF concentration for E was 1 ng/ml).
F: RKO and RKO--cat cells were transfected with B-luc (0.3 g) and treated with TNF as above.
response to TNF. Consistent with DNA binding activity and NF- stable transfectant cells (Figure 3E). Moreover, TNF-induced
NF-B driven reporter (Figure 3F) and NF-B DNA binding activi-B driven reporter, TNF treatment induced a significant amount
of TRAF1 expression in RKO cells in a dose- (data not shown) ties (data not shown) were also greatly inhibited. Thus, overex-
pression of -catenin is able to inhibit NF-B activity and itsand time-dependent manner (Figure 3D). Contrarily, TNF treat-
ment failed to induce TRAF1 expression in HCT116 cells (Figure downstream target gene expression.
Next, we asked whether -catenin is required for NF-B3D), and failed to further enhance TRAF1 expression in DLD-1
and SW480 cells, although there was a basal level of TRAF1 activity. To this end, we characterized the effects of depletion
of -catenin in -catenin-overexpressing cells, HCT116, whichexpression in these two cells lines (data not shown). To deter-
mine whether the effect was indeed due to -catenin, we further exhibit a high level of -catenin and suppressed NF-B activity
(Figure 3). HCT116 cells were sensitive to TNF-induced cellcharacterized the role of -catenin on NF-B in RKO and
HCT116 cells by both overexpression and depletion systems. death, as TNF treatment dramatically reduced survival cells
(Figure 4A). Introduction of GFP-p65, but not GFP as expectedFirst, we established RKO--cateninS37A stable transfectant
cells, and then examined TNF-induced TRAF1 expression. We (Schmid et al., 2000), inhibited TNF-induced cell death (Figure
4A). Introduction of GFP-p65 also induced B-driven reporterfound that TRAF1 expression was greatly inhibited in these
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Figure 4. Depletion of -catenin restores NF-B activity
A: HCT116 cells were transfected with -Gal (0.2 g) and GFP-p65 or GFP (1.6 g). Two days later, cells were treated with TNF for 24 hr. Percentage of
-Gal-positive cells was counted as surviving cells (viability).
B: HCT116 cells were transfected with B-luc reporter (0.2 g) with vector, pGFP-p65, and pGFP (1.6 g).
C: Immunoblot of cell lysates from HCT116 cells transfected with GFP-p65 or GFP (1.6 g) or none. Antibodies used in the assay were as indicated.
D: Immunoblot of cell lysates of cells transfected with siRNA--cat (1.6 g) or siRNA-NS (1.6 g) for 1 or 2 days as indicated (see Experimental procedures).
Before harvesting, cells were treated with TNF (10 ng/ml) for 9 hr.
E: EMSA analysis of NF-B (top) and Oct-1 (bottom) DNA binding activity. Nuclear extracts from cells transfected with siRNA--cat or siRNA-NS for 2 days,
then TNF treatment (10 ng/ml) or TNF plus INF- (10 ng/ml) for 15 min.
activity (Figure 4B) and TRAF1 expression (Figure 4C). Thus, with siRNA--cat as compared to cells treated with siRNA-NS
after stimulation with TNF or TNF plus IFN- (Figure 4E). Thep65 is able to activate its downstream target gene and induce
resistance to TNF-mediated apoptosis in HCT116 cells, which effect of siRNA--cat on NF-B was specific, since it did not
overexpress -catenin. We then used RNA interference to de- affect the DNA binding activity of another transcription factor,
plete -catenin in HCT116 cells and examined its effect on NF- Oct-1 (Figure 4E, bottom). These results indicate that depletion
B activities. We transfected small interfering RNA-targeting of -catenin in colon cancer cells expressing high levels of
-catenin mRNA (siRNA--cat) or nonspecific siRNA (siRNA- -catenin can release the suppression of NF-B activity and
NS) into HCT116 cells, and then examined the effect on NF-B restore the inducible expression of NF-B target genes. Taken
activity and its downstream target gene expression. We found together, the above observations indicate that -catenin is able
that treatment of HCT116 cells with siRNA--cat, but not siRNA- to exhibit an inhibitory effect on NF-B activity and its down-
NS, resulted in a reduced level of -catenin, indicating that stream target gene expression.
depletion of -catenin by siRNA method was effective (Figure
4D). Importantly, TNF stimulation was able to induce the NF- -catenin inhibits Fas expression
To investigate the physiological relevance of this crossregula-B target gene TRAF1 expression in cells treated with siRNA-
-cat, but not in those treated with siRNA-NS (Figure 4D). This tion, we examined the relationship of -catenin with another
important NF-B-regulated gene, Fas (CD95). Fas is a memberresult indicates that depletion of -catenin by siRNA restored
NF-B activation in response to TNF stimulation in the of TNF receptor family and expressed at high level in normal
colonic epithelial cells. In colon cancer cells and breast cancer-catenin-overexpressing HCT116 cells, suggesting that sup-
pressed NF-B is a result of -catenin overexpression. This cells, Fas was frequently found downregulated, which may con-
tribute to resistance to Fas-mediated apoptosis (von Reyher etconclusion was further supported by EMSA analysis, in which
NF-B DNA binding activity was increased in the cells treated al., 1998), and was proposed to allow cancer cells to escape
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from lymphocyte-mediated immune surveillance (O’Connell et treated siRNA--cat or siRNA-NS transfected cells with anti-
Fas antibody and measured Fas-mediated apoptosis by FACSal., 2000). However, the mechanism of Fas downregulation is
unclear. The p65 (RelA) subunit of NF-B is known to be required analysis. Consistent with the result from Fas expression, anti-
Fas antibody induced an increased apoptosis in cells trans-for Fas expression (Ouaaz et al., 1999). Since activation of
-catenin is also frequently found in colon and breast cancers fected with siRNA--cat as compared to the cells treated with
siRNA-NS (Figure 5E, right). This observation suggests that(Morin et al., 1997; Lin et al., 2000), and -catenin can inhibit
NF-B activity, it raises an interesting possibility that -catenin depletion of -catenin in colon cancer cells expressing high
levels of -catenin restores the expression of Fas and increasesmay inhibit NF-B activity and result in the downregulation of
Fas in cancer cells, thus allowing cancer cells to escape Fas the sensitivity of cells to Fas antibody-mediated apoptosis. As
depletion of -catenin resulted in both increased NF-B activityligand-induced cell death by lymphocyte. To investigate this
possibility, we wanted to confirm that NF-B is required for Fas (Figures 4D and 4E) and Fas expression in HCT116 cells (Figure
5E, left), we asked if repression of Fas expression by -cateninexpression by comparing Fas express level between MEF wild-
type and MEF p65/ cells. Fas expression level is much lower overexpression is through NF-B pathway. We then introduced
GFP-p65 into HCT116 cells and measured Fas expression inin p65 knockout MEF cells than in wild-type MEF cells (Figure
5A), indicating that the RelA subunit is indeed required for Fas GFP-positive cells. We found that GFP-p65, but not GFP, in-
creased Fas expression in HCT116 cells (Figure 5F), suggestingexpression. We then compared the expression levels of
-catenin and Fas in a panel of human breast cancer cell lines that repressed Fas expression is the result of suppressed NF-B
in these cells. Thus, inhibition of NF-B by -catenin was atby immunoblot. We found that there is an inverse relationship
between the expression of -catenin and that of Fas as well as least partially responsible for the suppressed Fas expression.
Taken together, these results indicate that depletion of-cateninTRAF1 (Figure 5B). In HBL-100 and MDA-MB-231 cells, in which
-catenin expression is low, the levels of Fas and TRAF1 expres- in colon cancer cells expressing high levels of -catenin can
restore NF-B activity (Figures 4D and 4E) and Fas expressionsion are high (Figure 5B); whereas in BT474, 468, and MCF7
cells, in which -catenin expression level is relatively high, the (Figure 5E), and increase the sensitivity of Fas-mediated apopto-
sis (Figure 5E).levels of Fas and TRAF1 are low (Figure 5B). This result implies
that high levels of expression of -catenin may be involved in
downregulation of Fas as well as TRAF1 expression. To deter- Downregulation of Fas in primary cancer tissues
Activation of -catenin has been reported in a number of can-mine the regulatory relationship of -catenin on Fas expression,
we then examined the Fas expression in RKO and RKO--cat cers, such as colon cancer and breast cancer (Polakis, 1999).
To further investigate the potential crossregulation of -catenincells. We found that the Fas expression level was much lower in
RKO--cat than in parental RKO cells (Figure 5C, left). Moreover, on Fas expression in vivo, we then examined the relationship
in primary cancer tissues. By immunohistochemical staining, wewith treatment of cells with anti-Fas antibody to stimulate Fas-
mediated cell death, we found that RKO--cat cells were more found a strong inverse correlation between the active -catenin
expression and the reduction of Fas expression (Figure 6 andresistant to Fas antibody-induced cell death than parental RKO
cells (Figure 5C, right), supporting the observation that Fas ex- Table 1). In the tumor tissues, in which -catenin expression is
low and inactive (membrane), Fas expression is high (Case 1pression was downregulated in these cells (Figure 5C, left). As
the increased level of -catenin in RKO--cat cells can suppress in Figure 6), whereas in tumor tissues in which -catenin expres-
sion is high and active (cytoplasmic and nuclear), Fas expressionNF-B activity (Figure 3), we asked if the repressed Fas expres-
sion was due to suppression of NF-B in these cells. To this is low (Case 2 in Figure 6). It should be mentioned that the two
images (Case 1 and Case 2) show adjacent spots of the sameend, we transfected RKO--cat cells with GFP-p65 or GFP, and
measured the Fas expression on the GFP-positive cells using tumor tissue with antibodies against either Fas or -catenin by
immunohistochemical staining. This indicates that the activationPE-labeled anti-Fas antibody by FACS analysis. We found that
introduction of GFP-p65 increased Fas expression in the RKO- of -catenin correlates very well with suppression of Fas in the
same tumor tissue area, which strongly suggests that activation-cat cells (Figure 5D), indicating that p65 derepresses -cat-
enin-mediated Fas repression. This result also suggests that of -catenin is involved in the downregulation of Fas expression
in vivo. Taken together, an inverse relationship was found be-the repressed Fas expression in-catenin stable transfectants is
due to suppression of NF-B (Figures 3E–3F). Thus, -catenin- tween aberrant activation of -catenin in colon and breast can-
cers and downregulation of Fas expression in vivo, whichmediated repression of Fas expression was at least partially
due to an inhibitory effect on NF-B pathway. Taken together, suggests that downregulation of Fas might be involved in
-catenin-mediated tumor progression.these results indicate that overexpression of -catenin is able
to downregulate Fas expression by inactivation of NF-B.
To further characterize the regulatory role of -catenin on Discussion
Fas expression, we then examined the effects of depletion of
-catenin on Fas expression in cancer cells expressing high In this study, we have shown that -catenin can physically
interact with NF-B (Figure 2) and inhibit its activity (Figures 1,levels of -catenin. Transfection of HCT116 cells with siRNA-
-cat, which resulted in decreased -catenin (Figure 5E, left, 3, and 4). Importantly, we have also shown that activation of
-catenin is involved in downregulation of Fas (Figure 5), a NF-top insert), was found to increase Fas expression, suggesting
that -catenin may suppress Fas expression in HCT116 cells B-regulated gene product, suggesting a novel mechanism for
-catenin-mediated oncogenesis; namely, -catenin inhibits(Figure 5E, left bottom). The effect is specific, since it was not
observed in the cells transfected with siRNA-NS (Figure 5E, NF-B activity, downregulating Fas expression, which may
allows cancer cells to escape immune surveillance.left). To determine the biological consequence of this effect,
we then examined Fas-mediated apoptosis in these cells. We -catenin inhibits NF-B through physical interaction, which
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Figure 5. -catenin inhibits Fas expression
A: Immunoblot of cell lysates from MEF wt or rela/ cells.
B: Immunoblot of cell lysates from human breast cancer cells with antibodies as indicated.
C: Left, immunoblot of cell lysates from RKO and RKO--catA cells. Right, cells were treated with cytokines, IFN- (10 ng/ml), and TNF (10 ng/ml) as indicated
for 24 hr and then treated with antibody to Fas (CH11) (0.5 g/ml) or normal mouse IgG (in presence of actinomycin D 5 ng/ml) for another 24 hr. Viable
cells were harvested and counted by Trypan Blue exclusion. Bars indicate the percent of surviving cells divided by the untreated control.
D: RKO--cat cells were transfected with GFP-p65 or GFP. Two days later, cells were harvested and measured for Fas-expression intensity on GFP-positive
cells by FACS analysis.
E: Left, HCT116 cells were transfected with siRNA--cat or siRNA-NS for 2 days, then harvested for Fas expression analysis by FACS. Bars show the intensity
of Fas expression in each group in comparison with that of control. Right, HCT116 cells were transfected with siRNA--cat or siRNA-SN for two days, then
treated with anti-Fas antibody (CH11) at 0.5 g/ml for 24 hr. The percentages of apoptotic cells were derived from analyzing the subG1 population labeled
with PI by FACS.
F: HCT116 cells were transfected with GFP-p65 and GFP for two days. Cells were then harvested and assayed for Fas expression as in D.
is independent of regulation of the IB- (Figures 1F and 2A) would be important for understanding the detailed mechanism
of the crossregulation by -catenin on the NF-B pathway.and TCF4 signaling pathways (Figure 1E). Thus, in addition to
acting as a transcriptional activator for TCF4 and androgen Inhibition of NF-B by -catenin may provide a plausible
mechanism for the observation from the GSK-3 knockoutreceptor (Yang et al., 2002), -catenin is also able to act as an
inhibitor participating in regulation of other signal transduction study in which the GSK-3 pathway has been shown to be
required for NF-B activation (Hoeflich et al., 2000). As-cateninpathways. The in vitro protein interaction analysis indicates that
the physical interaction between-catenin and NF-B is indirect is a major downstream target of GSK-3, depletion of GSK-3
may lead to an elevated -catenin expression and suppressedand an additional cellular protein is required (Figures 2B–2D).
This implies that the interaction between -catenin and NF-B NF-B activity. However, in the original study, there was no
evidence of -catenin accumulation in GSK-3 (/) cells. Al-may be subject to another level of regulation. Thus, identification
of the interactive domain in -catenin and the intermediate pro- though severe cell death was detected in the hepatocyte of the
GSK-3 (/) mice, it is not clear whether -catenin mighttein for this interaction, which require further investigation,
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Figure 6. -catenin inversely correlates with Fas
expression in colon cancer
Representative human colon primary tumor tis-
sues samples by immunohistochemistry staining.
Case 1, when -catenin is inactive (primarily in
the membrane) (A), Fas expression is high (B)
(two stainings from adjacent areas). Case 2,
when -catenin is active (in the cytoplasm and
the nucleus) (C), Fas expression level is low (D).
contribute to the hepatocyte apoptosis, or whether it could be -catenin, can inhibit cellular sensitivity to apoptosis induced
by two anticancer agents, vincristine (VCR) and vinblastine (VBL)caused by other mechanisms in GSK-3 (/) mice. In our
study, we found that -catenin can inhibit NF-B. In addition, (Chen et al., 2001). However, this activity requires -catenin/
TCF-mediated transcription, suggesting a different pathway isinhibition of GSK-3 with GSK-3 inhibitors in human colon
and breast cancer cell lines increased-catenin and suppressed involved.
NF-B has been shown to mediate inhibition of TNF- andboth basal and TNF-induced NF-B activity, suggesting that
-catenin can serve a mediator for inhibition of NF-B (data other anticancer drug-induced apoptosis (Liu et al., 1996; Wang
et al., 1996). Aberrant activation of NF-B has also been foundnot shown). Taken together, our study strongly suggests that
-catenin is a major mediator for the crossregulation of NF-B in various types of cancers, which associate with malignant and
apoptosis-resistant properties (Bours et al., 2000). In this study,by the GSK-3 pathway, although other mechanisms are not
excluded. we found that -catenin inhibits NF-B. However, as NF-B
-catenin has been shown to be proapoptotic. This property exhibits a dual role in regulation of apoptosis and oncogenesis,
is independent of both TCF4 and the transcriptional function of the phenotypic effects or biological consequences of -catenin
-catenin (Kim et al., 2000). However, the mechanism of this activation may be dependent on the cellular context and/or
observation is not clear. Similarly, the proapoptotic activity of combined with the activation of particular signaling pathways.
-catenin has also been observed in vivo. It was shown that For example, it has been recently shown that depletion of NF-
overexpression of an activated form of -catenin in transgenic B in the rela (NF-B) knockout mice results in a malignantly
mice results in a 3- to 4-fold increase of apoptotic cells in the transformed phenotype of embryonic fibroblast cells regardless
intestinal villi of transgenic mice (Romagnolo et al., 1999; Wong of increased sensitivity to TNF (Gapuzan et al., 2002). It should
et al., 1998). The results of our study may provide a plausible be mentioned that many protooncogenes, such as ras (Cheng
mechanism for these observations. -catenin is also implicated and Meinkoth, 2001; Trent et al., 1996), c-myc (Eischen et al.,
to be antiapoptotic in a different system. A recent report demon- 2001; Hsu et al., 1995), and E2F-1 (Hunt et al., 1997; Macleod,
strates that Wnt-1, which inhibits GSK-3 and increases 1999), have all been shown to have a proapoptotic activity when
activated and/or overexpressed. As these genes also play a
regulatory function in normal cells, association of a proliferative
activity with proapoptotic activity may be normal for host to
Table 1. Summary of primary tumor tissue sample maintain homeostasis. Thus, the association of proapoptic and
A: Summary of colon cancer primary tissue (p  0.0351) oncogenic activities by -catenin may not be a surprise.
Fas is expressed in normal epithelial cells in colon and breast-catenin -catenin	 Total
Fas 2 (10.5%) 15 (78.9%) 17 (89.5%) tissue, which are sensitive to Fas-induced apoptosis (von Rey-
Fas	 2 (10.5%) 0 (0%) 2 (10.5%) her et al., 1998). This mechanism is important in maintaining the
Total 4 (21%) 15 (78.9%) 19 (100%) homeostasis of these tissues. However, Fas is downregulated or
B: Summary of breast cancer primary tissue (p  0.0256) lost in the majority of colon carcinomas, which usually leads to
resistance to Fas-mediated apoptosis. Downregulation of Fas-catenin -catenin	 Total
Fas 0 (0%) 5 (33%) 5 (33%) is suggested to be an important mechanism for cancer cells,
Fas	 7 (46.7%) 3 (20%) 10 (66%) especially in colon cancer, to escape Fas ligand-mediated im-
Total 7 (46.7%) 8 (53%) 15 (100%) mune surveillance (Butler et al., 1998). The mechanisms of Fas
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downregulation in different cancers are unclear. The promoter the dual role of -catenin on cell biology, which goes through
of the Fas gene contains two NF-B binding sites, which are NF-B, may be dependent on cellular context and tissue envi-
required for NF-B-mediated activation. However, NF-B acti- ronment.
vation may be required but not sufficient for Fas expression, as In summary, we have shown that-catenin can inhibit NF-B
a concert of cytokines was required for strong induction of Fas in an IB-independent and TCF-4-independent manner. -cat-
expression (Chan et al., 1999; Ouaaz et al., 1999). In this study, enin forms a complex with NF-B components (p65 and p50).
we demonstrated that -catenin can inhibit NF-B, which may -catenin can inhibit NF-B transactivation, DNA binding
limit Fas expression. This observation was demonstrated in vitro activity, and target gene expression. Importantly, activation of
and strongly supported by analysis in vivo. By both overexpres- -catenin inhibits expression of Fas, a NF-B target gene. More-
sion and depletion systems, we have shown that -catenin over, an inverse correlation between -catenin and Fas expres-
limits the expression of the NF-B target Fas. Moreover, the sion was identified in both human colon and breast tumor tis-
expression level of Fas was found to inversely correlate with sues. Thus, the results of this study provide a novel mechanism
that of -catenin in human breast cancer cell lines, and more for the role of -catenin on tumor progression.
importantly in primary tumor tissues. Thus, -catenin may also
be able to contribute to tumorigenicity through downregulation Experimental procedures
of Fas and/or prevention of Fas-mediated apoptosis, a novel
Cell culture and transfection assaysmechanism for -catenin-involved tumor progression. NF-B
All cell lines were grown in Dulbecco’s modified Eagle’s medium/F12 (LifeRelA (p65) has been shown to be essential but not sufficient
Technologies, Inc) supplemented with 10% fetal bovine serum. HEK 293for Fas expression in MEF cells. Other members of NF-B family,
cells, human colon cancer cell lines SW480, DLD-1, HCT116, and RKOsuch as p50 and c-Rel, are also involved in the regulation of
(Morin et al., 1997; Sasaki et al., 2000), breast cancer cell lines MDA-MB-
Fas expression (Zheng et al., 2001). Thus, a primary function 231, MCF-7, BT474, and 468, and the immortalized breast cell line HBL100
of NF-B may be to promote Fas-induced cell death through were used. Transient transfections were performed with NF-B-driven-lucif-
the enhancement of Fas expression, rather than inhibit cell death erase plasmid (B-luc.) as reporter, and p65, -catenin, or active mutant
through expression of survival genes (Zheng et al., 2001). It -cateninS37A (-catS37A), APC, or mutant APC as effectors. The ratio of
effectors and reporter was as indicated. 293 -cateninS45Y stable transfec-should be noted that RelA is required for Fas expression in
tants (293--cat A and B) were as described (Lin et al., 2000). The transfectionMEF cells, although it is dispensable for Fas expression in T
agents LPD1 or SN liposomes were incubated with DNA in serum-free medialymphocytes (Zheng et al., 2001), suggesting a cell type differ-
for 30 min before adding to cells and incubating for 3 hr. RKO stable transfec-ence. Thus, the detailed mechanism remains to be investigated
tants were established by transfection with -cateninS37A plasmid. Cellof how -catenin affects Fas expression in human colon and/
lysates for luciferase activity were collected 48 hr after transfection, and cells
or breast cancers and the role of this function in -catenin- were treated with TNF (10 ng/ml) 8 hr before harvesting, unless otherwise
mediated oncogenesis. indicated. In all the experiments, the total DNA is kept constant by addition
NF-B plays a dual role in regulating apoptosis. For exam- of the empty vector. Plasmid pRL-tk (Promega) was used as internal control
ple, NF-B has been shown to be required for p53-induced in all transfection assays. Similar results were obtained when repeated with
-galactosidase as an internal control (data not shown). Cell viability wasapoptosis and for induction of resistance to TNF-induced apo-
determined either by number of blue cells stained by -gal or through trypanptosis (Ryan et al., 2000). It is likely that NF-B is required for
blue exclusion as indicated in the legends to Figures 1, 4, and 5. Error barsinduction of a subset of survival genes against TNFR-mediated
are the mean 
 standard error. Apoptosis induction via Fas pathway wasapoptosis, as well as a subset of the genes essential for p53-
performed by using anti-Fas antibody (CH11, Upstate) at 50 ng/ml for 24 hr.induced apoptosis. In this study, we showed that -catenin
plays a dual role in regulating Fas- and TNFR-mediated apopto-
Immunoprecipitation (IP) and immunoblot
sis. Moreover, we have shown that this function may go through IP was performed with 2 g of antibodies against p65 or p50 (normal IgG
the NF-B pathway. The results of this study suggest that NF- as a negative control) in 1.0 mg whole lysate protein (TNF treatment was
B is at least partially required for -catenin-mediated dual 30 min, at 10 ng/ml). Samples were first precleared with a nonspecific IgG
regulation of both Fas- and TNFR-mediated apoptosis. In fact, antibody. Precleared lysates were then incubated with antibody either to
p65 or p50 for 1.5 hr, then incubated overnight with protein G agarose.depletion of -catenin in colon cancer HCT116 cells expressing
Samples were washed 4 times with phosphate-buffered solution with 0.1%high levels of -catenin did increase Fas expression and Fas-
tween and then subjected to immunoblot as indicated. Cell lysates weremediated apoptosis (Figure 5E), whereas overexpression of
separated by SDS/PAGE in a 10% acrylamide gel and transferred onto-catenin increased the sensitivity of Saos-2 cells to TNF-
nitrocellulose membrane for immunoblot. Antibodies to p65 (A), p50 (C-19),induced apoptosis (Figure 1D). Because of the dual role in the
IB- (C-21), TRAF1 (G-20, H132), GFP (FL), and Fas (c-20) were from Santa
regulation of apoptosis, disruption of Fas-mediated apoptosis Cruz. Antibody to -catenin was from BD Transduction Laboratories.
may therefore be particularly important for -catenin-mediated
oncogenesis in tissues, such as colon, in which the Fas pathway In vitro translation and GST pull down
plays a major role in maintaining homeostasis. This possibility 35S-Met-labeled p65 was in vitro translated from pBS-p65 (T7) using a TNT
T7 quick-coupled translation/transcription system (Promega). 35S-Met la-was strongly supported by the analysis in vivo, as an inverse
beled p50 proteins were in vitro translated from pBS-p105 (T3) using a TNTrelationship was identified between -catenin and Fas expres-
T3-coupled reticulocyte lysate system (Promega). pBS-p105 plasmid wassion in both human colon cancers and breast cancers. Because
first digested with Best EII, which cut at site 1572 before use. Translationof the dual regulatory role on the outcome in cells, it is likely that
from this digested plasmid resulted in a protein product close to p50. Inthe oncogenic role of -catenin also requires the cooperation of
vitro-translated proteins were mixed either with GST--catenin or GST (10
specific oncogenic alterations during tumor progression. For g) in presence or absence of whole or p65- or p50-depleted (by 3 times
example, deregulated -catenin was found to cooperate with IP with excess antibody to p65 or p50) RKO cell lysate (100 g) for 2 hr at
ras in cell transformation when ARF and p53 are inactively mu- 4C, then pulled down by glutathione-agarose, and subjected to SDS-PAGE
(10%) and autography.tated (Damalas et al., 2001). Thus, the biological outcome of
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Bours, V., Bentires-Alj, M., Hellin, A.C., Viatour, P., Robe, P., Delhalle, S.,Electrophoresis mobility shift assay (EMSA)
Benoit, V., and Merville, M.P. (2000). Nuclear factor-B, cancer, and apopto-Nuclear extracts from normal or TNF-treated cells were used in EMSA with
sis. Biochem. Pharmacol. 60, 1085–1089.an oligonucleotide probe containing the NF-B binding site as described
(Zhou et al., 2000) or with the Oct-1 binding site as described (Hoeflich et Butler, L.M., Hewett, P.J., Butler, W.J., and Cowled, P.A. (1998). Down-
al., 2000). Eighty-fold of cold wild-type or mutant NF-B oligonucleotides regulation of Fas gene expression in colon cancer is not a result of allelic
were used for competition in the nuclear extracts of control or TNF-treated loss or gene rearrangement. Br. J. Cancer 77, 1454–1459.
(15 min) 293 cells; doses are as indicated. Antibodies used for supershifting
Chan, H., Bartos, D.P., and Owen-Schaub, L.B. (1999). Activation-dependentthe complex were as indicated. Antibodies to p65 (A), p50 (C-19), p300
transcriptional regulation of the human Fas promoter requires NF-B p50-(C-20), and Oct-1 (C-21) for supershift were from Santa Cruz.
p65 recruitment. Mol. Cell. Biol. 19, 2098–2108.
Flow cytometry Chen, S., Guttridge, D.C., You, Z., Zhang, Z., Fribley, A., Mayo, M.W., Kita-
Cells were harvested, washed once with PBS, and stained with PE-conju- jewski, J., and Wang, C.Y. (2001). Wnt-1 signaling inhibits apoptosis by
gated mouse anti-Fas (CD95) antibody (DX2) or normal IgG1 (Pharmigen) activating -catenin/T cell factor-mediated transcription. J. Cell Biol. 152,
for 30 min at room temperature. Cells were then washed once with PBS, 87–96.
fixed in 2% paraformaldahyde, and analyzed using Becton Dickinson flow
Cheng, G., and Meinkoth, J.L. (2001). Enhanced sensitivity to apoptosis incytometer. For cells transfected with GFP or GFP-p65, GFP-positive cells
Ras-transformed thyroid cells. Oncogene 20, 7334–7341.were analyzed for PE intensity. The mean values of PE intensity minus the
background (PE-labeled normal mouse IgG) were used as relative Fas protein Crawford, H.C., Fingleton, B.M., Rudolph-Owen, L.A., Goss, K.J., Rubinfeld,
expression level. B., Polakis, P., and Matrisian, L.M. (1999). The metalloproteinase matrilysin
is a target of -catenin transactivation in intestinal tumors. Oncogene 18,
Immunohistochemical staining 2883–2891.
Tissue samples were deparaffinized and then subjected to a gradient of
Damalas, A., Kahan, S., Shtutman, M., Ben-Ze’ev, A., and Oren, M. (2001).alcohol and washed five times. They were trypsinized in 0.05% trypsin in
Deregulated -catenin induces a p53- and ARF-dependent growth arrestPBS and treated with 0.3% H2O2 in methanol. Then they were treated with
and cooperates with Ras in transformation. EMBO J. 20, 4912–4922.10% horse serum for 30 min. Sections were incubated with primary antibod-
ies overnight, either -catenin mAb (1:50 dilution) or Fas (Transduction Labo- Eischen, C.M., Roussel, M.F., Korsmeyer, S.J., and Cleveland, J.L. (2001).
ratories, 1:100). Sections were incubated with secondary antibodies Bio- Bax loss impairs Myc-induced apoptosis and circumvents the selection of
Anti mouse and rabbit IgG (1:200 dilution) for 1 hr and then incubated with p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 21,
avidin biotin-peroxidase complex diluted in PBS and visualized with amino- 7653–7662.
ethyl carbazole chromogen stock solution. The Fisher exact test was used for
Gapuzan, M.E., Yufit, P.V., and Gilmore, T.D. (2002). Immortalized embryonicstatistical analysis with p 0.05 as statistical significance for Fas expression.
mouse fibroblasts lacking the RelA subunit of transcription factor NF-B
have a malignantly transformed phenotype. Oncogene 21, 2484–2492.Small interfering RNA transfection
Small interfering RNA (siRNA) duplex oligo (Dharmacon) targeting -catenin Gerritsen, M.E., Williams, A.J., Neish, A.S., Moore, S., Shi, Y., and Collins,
mRNA (5 AAG UCC UGU AUG AGU GGG AAC 3) or a nonspecific duplex T. (1997). CREB-binding protein/p300 are transcriptional coactivators of p65.
oligo as a negative control (5 AAC AGU CGC GUU UGC GAC UGG 3) Proc. Natl. Acad. Sci. USA 94, 2927–2932.
(1.6 g/35 mm plate or 12.8 g/100 mm plate) were transfected using
Ghosh, S., May, M.J., and Kopp, E.B. (1998). NF-B and Rel proteins:Lipofectamine (Invitrogen) at a ratio of 1 g RNA to 3 l Lipofectamine.
evolutionarily conserved mediators of immune responses. Annu. Rev. Immu-Experiments were performed on day 1 after transfection.
nol. 16, 225–260.
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